Journal: iScience

Article Title: VPS33B regulates MHC class II antigen presentation in dendritic cells to drive CD4 T cell immunity

doi: 10.1016/j.isci.2026.116052

Figure Lengend Snippet: VPS33B-deficient DCs are impaired in the presentation of MHC class II associated peptides derived from exogenous antigens (A) Representative flow plots of surface 15G4 expression on VPS33B WT and VPS33B ΔCSF1R BMDCs left US or stimulated with LPS (100 ng/mL) for the indicated time points. Plots were pre-gated on live, CD11b + , CD11c + cells. Graphical quantification of % 15G4 + BMDCs and 15G4 MFI (mean fluorescence intensity) to the right. (B) Representative flow plots of surface YAe expression on VPS33B WT and VPS33B ΔCSF1R BMDCs left US or pulsed with I-E d tetramer (10 μg/mL) for 1 h before being chased for the indicated time points. Plots were pre-gated on live, CD11b + , CD11c + cells. Graphical quantification of % YAe + BMDCs to the right. (C) Representative flow plots of CTV-stained OT-II T cells (pre-gated on live, CD4 + , CD8 − ) co-cultured with VPS33B WT and VPS33B ΔCSF1R sDCs in the presence or absence of OVA 323-339 (0.01 and 0.1 μM) and LPS (100 ng/mL) for 72 h. Graphical quantification of % proliferating (CTV-diluted) OT-II T cells to the right. (D) Representative flow plots of % CD44 + OT-II T cells co-cultured with VPS33B WT and VPS33B ΔCSF1R sDCs in the presence or absence of OVA 323-339 (0.01 and 0.1 μM) and LPS (100 ng/mL) for 72 h. Graphical quantification of % CD44 + OT-II T cells to the right. NP = no peptide (OVA 323-339 ). Error bars shown as mean ± SEM. (A–D) n = 2–4 independent experiments. Statistical analysis was performed by two-way ANOVA. ∗ p < 0 . 01 , ∗∗ p < 0 . 01 , ∗∗∗ p < 0 . 01 , ∗∗∗∗p < 0 . 0001 , n.s. = not significant.

Article Snippet: OVA 323-339 , Invivogen , Cat#vac-isq.

Techniques: Derivative Assay, Expressing, Fluorescence, Staining, Cell Culture

Journal: Bioactive Materials

Article Title: Splenic dendritic cell-targeting mRNA transfection of H-type ionizable lipid-based LNPs for enhancing tumor immunotherapy

doi: 10.1016/j.bioactmat.2026.02.018

Figure Lengend Snippet: Anti-tumor effects of mOVA/H 18 NPs as a preventive tumor vaccine. (A) Schematic illustration of experiment design. C57BL/6J mice were vaccinated twice on Day −14 and Day −7 through intravenous injection. On Day 0, B16-OVA cells were inoculated subcutaneously on C57BL/6J mice. (B) Tumor growth curves and (C) survival rate of B16-OVA-bearing mice (n = 6). The survival rates of the two groups were analyzed using a log-rank test. Individual tumor growth curves of mice in (D) PBS group, (E) OVA protein group, (F) mOVA/MC3-LNPs group, and (G) mOVA/H 18 NPs group (n = 6). Representative flow cytometry contour plots (H) and quantification (I) of the percentage of T EM in CD8 + T cells in the spleen (n = 3).

Article Snippet: OVA protein was purchased from Shanghai Yuanye Bio-Technology Co., Ltd (Shanghai, China).

Techniques: Injection, Flow Cytometry

Journal: STAR Protocols

Article Title: Protocol for an in vivo CRISPR screen for germinal center B cells in mice using ecotropic retrovirus

doi: 10.1016/j.xpro.2026.104586

Figure Lengend Snippet: Immunization experiment scheme for in vivo screen Host mice (IOMA gl) were immunized with OVA in alum. At week 2 after immunization, B cells from B1-8 hi , LSL-Cas9, AID-Cre, Kappa KO animals were transduced with pooled sgRNA library retrovirus and adoptively transferred to the hosts. Subsequently, the host animals were boosted with NP-OVA in alum at day 0 and 2 and administered with anti-DEC205-OVA mAb at day 6.5. Spleens were harvested and processed for cell sorting at day 10.

Article Snippet: NP-OVA (conjugation ratio: 21) , Biosearch Technologies , cat# N-5051.

Techniques: In Vivo, Transduction, FACS